{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:10:41Z","timestamp":1789726241511,"version":"4.0.1"},"reference-count":39,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2016,9,12]]},"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Case reports of capecitabine cardiotoxicity resemble those seen with intravenous 5-fluorouracil (5-FU) with chest pain as the predominant manifestation, but few studies of capecitabine cardiotoxicity are available. We aimed to determine the incidence of symptomatic cardiotoxicity from capecitabine in patients with breast cancer and to identify risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We reviewed medical records of consecutive women with breast cancer treated with capecitabine (1000\u2005mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      two times per day) from 2002 to 2012 at one institution.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>22 of 452 patients (4.9%) (95% CI 2.9% to 6.9%) had symptoms of cardiotoxicity (chest pain: n=13, dyspnoea: n=9, palpitations: n=2). 11 patients had changes on ECG (atrial fibrillation: n=5, ST deviations: n=3, T-wave abnormalities: n=2 and QTc prolongation: n=1). 2 patients (0.4%) sustained acute myocardial infarction. 1 patient (0.2%) developed cardiac arrest with lethal outcome. 4 of 6 patients (66%) retreated with capecitabine had recurrent symptoms at retreatment. Cardiac comorbidity (p=0.001), hypercholesterolaemia (p=0.005) and current smoking (p=0.023) were risk factors for cardiotoxicity in univariate analyses and remained significant when adjusted for age. Patients with cardiac comorbidity were 5.5 times (95% CI 2.0 to 14.8) more likely to develop cardiotoxicity. In the subgroup of patients with apparently no cardiac comorbidity, the incidence of cardiotoxicity was lower (3.7%) and hypercholesterolaemia (p=0.035) and current smoking (p=0.020) were risk factors of cardiotoxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The incidence of cardiotoxicity from capecitabine resembles that of intravenous 5-FU (\u22485%). Cardiac comorbidity, hypercholesterolaemia and current smoking were associated with development of cardiotoxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2016-012798","type":"journal-article","created":{"date-parts":[[2016,10,19]],"date-time":"2016-10-19T23:23:50Z","timestamp":1476919430000},"page":"e012798","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":67,"title":["Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer"],"prefix":"10.1136","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2335-8219","authenticated-orcid":false,"given":"Anne","family":"Polk","sequence":"first","affiliation":[{"name":"Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark"},{"name":"Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid","family":"Shahmarvand","sequence":"additional","affiliation":[{"name":"Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Vistisen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merete","family":"Vaage-Nilsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn Ole","family":"Larsen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Schou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorte Lisbeth","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,10,19]]},"reference":[{"key":"2025121508333366000_6.10.e012798.1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2174\/1568011023354146","article-title":"The prodrugs of 5-fluorouracil","volume":"2","author":"Malet-Martino","year":"2002","journal-title":"Curr Med Chem Anticancer Agents"},{"key":"2025121508333366000_6.10.e012798.2","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","article-title":"Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study","volume":"19","author":"Hoff","year":"2001","journal-title":"J Clin Oncol"},{"key":"2025121508333366000_6.10.e012798.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.01.005"},{"key":"2025121508333366000_6.10.e012798.4","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","article-title":"Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study","volume":"19","author":"Van Cutsem","year":"2001","journal-title":"J Clin Oncol"},{"key":"2025121508333366000_6.10.e012798.5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf089"},{"key":"2025121508333366000_6.10.e012798.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0828-282X(06)70905-9"},{"key":"2025121508333366000_6.10.e012798.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2007.06.152"},{"key":"2025121508333366000_6.10.e012798.8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf035"},{"key":"2025121508333366000_6.10.e012798.9","first-page":"3349","article-title":"Acute myocardial infarction after capecitabine treatment: not always vasospasm is responsible","volume":"125","author":"Guvenc","year":"2012","journal-title":"Chin Med J"},{"key":"2025121508333366000_6.10.e012798.10","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1023\/A:1011152931300","article-title":"Coronary spasm induced by capecitabine","volume":"12","author":"Schnetzler","year":"2001","journal-title":"Ann Oncol"},{"key":"2025121508333366000_6.10.e012798.11","doi-asserted-by":"publisher","DOI":"10.1177\/1078155211399164"},{"key":"2025121508333366000_6.10.e012798.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2009.02144.x"},{"key":"2025121508333366000_6.10.e012798.13","first-page":"320","article-title":"Capecitabine may induce coronary artery vasospasm","volume":"53","author":"Tsiamis","year":"2012","journal-title":"Hellenic J Cardiol"},{"key":"2025121508333366000_6.10.e012798.14","doi-asserted-by":"crossref","first-page":"pii: bcr09.2008.0964","DOI":"10.1136\/bcr.09.2008.0964","article-title":"Capecitabine induced acute coronary syndrome","volume":"2009","author":"Yung","year":"2009","journal-title":"BMJ Case Rep"},{"key":"2025121508333366000_6.10.e012798.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2013.03.005"},{"key":"2025121508333366000_6.10.e012798.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.03.004"},{"key":"2025121508333366000_6.10.e012798.17","doi-asserted-by":"publisher","DOI":"10.1517\/14740330902733961"},{"key":"2025121508333366000_6.10.e012798.18","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930115)71:2<493::AID-CNCR2820710235>3.0.CO;2-C"},{"key":"2025121508333366000_6.10.e012798.19","doi-asserted-by":"publisher","DOI":"10.5603\/CJ.2012.0084"},{"key":"2025121508333366000_6.10.e012798.20","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-005-0178-1"},{"key":"2025121508333366000_6.10.e012798.21","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1159\/000331645","article-title":"Clinical and electrocardiography changes in patients treated with capecitabine","volume":"57","author":"Koca","year":"2011","journal-title":"Chemotherapy"},{"key":"2025121508333366000_6.10.e012798.22","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-007-0250-9"},{"key":"2025121508333366000_6.10.e012798.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.03.027"},{"key":"2025121508333366000_6.10.e012798.24","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf108"},{"key":"2025121508333366000_6.10.e012798.25","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/j.1875-9114.1997.tb03748.x","article-title":"Symptomatic cardiotoxicity associated with 5-fluorouracil","volume":"17","author":"Meyer","year":"1997","journal-title":"Pharmacotherapy"},{"key":"2025121508333366000_6.10.e012798.26","first-page":"E27","article-title":"Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease","volume":"93","author":"Tsibiribi","year":"2006","journal-title":"Bull Cancer"},{"key":"2025121508333366000_6.10.e012798.27","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.1989.7.4.509","article-title":"Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study","volume":"7","author":"Rezkalla","year":"1989","journal-title":"J Clin Oncol"},{"key":"2025121508333366000_6.10.e012798.28","doi-asserted-by":"publisher","DOI":"10.3109\/02841869009091790"},{"key":"2025121508333366000_6.10.e012798.29","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/030089168206800609","article-title":"Cardiac toxicity of 5-fluorouracil: a study on 1083 patients","volume":"68","author":"Labianca","year":"1982","journal-title":"Tumori"},{"key":"2025121508333366000_6.10.e012798.30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.3953"},{"key":"2025121508333366000_6.10.e012798.31","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu055"},{"key":"2025121508333366000_6.10.e012798.32","first-page":"430","article-title":"A retrospective study of cardiotoxicities induced by 5-fluouracil (5-FU) and 5-FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer Hospital & Research Center","volume":"62","author":"Khan","year":"2012","journal-title":"J Pak Med Assoc"},{"key":"2025121508333366000_6.10.e012798.33","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyi071"},{"key":"2025121508333366000_6.10.e012798.34","doi-asserted-by":"crossref","first-page":"461","DOI":"10.5152\/akd.2010.147","article-title":"Two cases of coronary vasospasm induced by 5-fluorouracil","volume":"10","author":"Atar","year":"2010","journal-title":"Anadolu Kardiyol Derg"},{"key":"2025121508333366000_6.10.e012798.35","doi-asserted-by":"publisher","DOI":"10.1592\/phco.31.2.226"},{"key":"2025121508333366000_6.10.e012798.36","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ajem.2010.10.025","article-title":"Initial dose effect of 5-fluorouracil: rapidly improving severe, acute toxic myopericarditis","volume":"30","author":"\u00c7al\u0131k","year":"2012","journal-title":"Am J Emerg Med"},{"key":"2025121508333366000_6.10.e012798.37","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5152\/eajm.2011.11","article-title":"Coronary vasospasm secondary to 5-fluorouracil and its management: case report","volume":"43","author":"Yildirim","year":"2011","journal-title":"Eurasian J Med"},{"key":"2025121508333366000_6.10.e012798.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209825"},{"key":"2025121508333366000_6.10.e012798.39","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu178"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2016-012798","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:33:43Z","timestamp":1765816423000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2016-012798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,10,19]]},"published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1136\/bmjopen-2016-012798"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2016-012798","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10]]}}}